Finanzas de Legend Biotech Corp (LEGN)LEGNLegend Biotech Corp

Evaluating the bottom line, Legend Biotech Corporation maintains a gross margin of 64.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.89%, while the net margin is 8.57%. These profitability ratios, combined with a Return on Equity (ROE) of -8.09%, provide a clear picture of how effectively LEGN converts its operational activities into shareholder value.

In the context of the broader market, LEGN competes directly with industry leaders such as OGN and ARQT. With a market capitalization of $3.59B, it holds a significant position in the sector. When comparing efficiency, LEGN's gross margin of 64.54% stands against OGN's 54.36% and ARQT's 91.58%. Such benchmarking helps identify whether Legend Biotech Corporation is trading at a premium or discount relative to its financial performance.

In Q2 2026, Legend Biotech reported a profit of $33.2 million, a significant turnaround from a loss of $125.4 million in Q2 2025. Revenue surged by 52% to $387.5 million, driven by strong sales of CARVYKTI, which generated $657 million, a 50% increase year-over-year.